Skip to main content


About the DZI

The Deutsches Zentrum Immuntherapie (DZI) evolves the results of basic research into clinical applications

This translational approach allows us to treat patients with chronic inflammatory diseases, autoimmune diseases and cancer using targeted immunotherapy – with significant success.

Focus on the patient’s wellbeing

Our clinical centre has over 2000 square metres of collaborative workspace for immunotherapy experts specialised in dermatology, gastroenterology, haematology and oncology, clinical immunology, pneumology and rheumatology. Our aim: to ensure an efficient transfer of research findings into innovative strategies for the diagnosis and treatment of chronic inflammatory diseases and cancer.

History and mission

The DZI follows a long tradition of the FAU’s Faculty of Medicine in immunology research of inflammatory diseases and cancer. Based on the pioneering and revolutionary research of Adolf Kussmaul, the first person to describe polyarteritis nodosa (an inflammation of the blood vessels), as well as the Nobel prize winner Harald zur Hausen, the pioneer behind the vaccine against cervical cancer, there has always been a fascination for translational immunology and immunotherapy in Erlangen, which continues to be pursued by the Erlangen-based researchers Martin Röllinghoff, Bernhard Fleckenstein and Joachim Kalden.

It is for this reason that the DZI focuses on translational immunology and immunotherapy for inflammatory diseases and cancer.